Novartis
NVS
NVS
936 hedge funds and large institutions have $22.2B invested in Novartis in 2017 Q3 according to their latest regulatory filings, with 70 funds opening new positions, 348 increasing their positions, 335 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
2% more capital invested
Capital invested by funds: $21.7B → $22.2B (+$474M)
0.06% less ownership
Funds ownership: 11.09% → 11.03% (-0.06%)
5% less funds holding in top 10
Funds holding in top 10: 40 → 38 (-2)
Holders
936
Holding in Top 10
38
Calls
$41.3M
Puts
$22.2M
Top Buyers
| 1 | +$161M | |
| 2 | +$127M | |
| 3 | +$64.6M | |
| 4 |
Morgan Stanley
New York
|
+$42.5M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$29.6M |
Top Sellers
| 1 | -$472M | |
| 2 | -$32.8M | |
| 3 | -$32.2M | |
| 4 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$18.7M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$16M |